Copyright © Inderes 2011 - present. All rights reserved.
  • Seneste
  • Markeder
    • Aktieoversigt
    • Finanskalender
    • Udbyttekalender
    • Research
    • Artikler
    • Transskriptioner
  • InderesTV
  • Forum
  • Om os
    • Fulgte selskaber
    • Team

Du bruger tilsyneladende en bredere skærm. Vil du gerne give denne side en bredere visningsoplevelse?

ExpreS2ion Biotechnologies – Presentation of Q3 2023 results

Af HC Andersen Capital
ExpreS2ion Biotech Holding

This morning, Expres2ion Biotechnology released its Q3 2023 results. In a virtual live event today with CEO Bent Frandsen and CFO Keith Alexander we went through the results and achievements of the quarter. The management gave an update on the pipeline and lastly a status on the new strategy, focusing more on projects with shorter time to development and less risk.

ExpreS2ion Biotechnologies is a Danish pharmaceutical company, which focuses on the development of vaccines through the use of its non-viral Drosophila S2 cells-based expression system.

Disclaimer: HC Andersen Capital receives payment from ExpreS2ion Biotechnologies for a Corporate Visibility/Digital IR subscription agreement. /Michael Friis 14.45, 16 November 2023.

Seneste videoer

Catena Media, Audiocast, Q4'25
10.02.2026, 18.00 Catena Media
Sdiptech, Webcast, Q4'25
10.02.2026, 14.00 Sdiptech
Nokian Tyres plc, Audiocast, Q4'25
10.02.2026, 13.00 Nokian Tyres
Remedy Entertainment, Webcast, Q4'25
10.02.2026, 11.00 Remedy Entertainment
Nyfosa, Q4 & Investor Update, 2026
10.02.2026, 10.30 Nyfosa
Vis alle videoer
Find os på de sociale medier
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Tag kontakt
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • Om os
  • Vores team
  • Karriere
  • Inderes som en investering
  • Tjenester for børsnoterede virksomheder
Vores platform
  • FAQ
  • Servicevilkår
  • Privatlivspolitik
  • Disclaimer
Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.